Literature DB >> 2706189

Pharmacokinetics of felodipine in patients with impaired renal function.

B Edgar1, C G Regårdh, P O Attman, M Aurell, H Herlitz, G Johnsson.   

Abstract

1. The pharmacokinetics of felodipine and its effects on blood pressure and heart rate were studied in eight male patients aged between 28 and 57 years with a glomerular filtration rate, GFR, between 8 and 68 ml min-1, following single i.v. and oral administration. 2. Clearance, Cmax, AUC, Vss and V, of felodipine were unaffected by the renal disease. The metabolite excretion (14C-labelled) was slower than in healthy subjects. Initial renal clearance of these metabolites correlated with individual GFR values. The total amount of the dose excreted in the urine was also decreased.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2706189      PMCID: PMC1379706          DOI: 10.1111/j.1365-2125.1989.tb05336.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects.

Authors:  S Landahl; B Edgar; M Gabrielsson; M Larsson; B Lernfelt; P Lundborg; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

2.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

3.  Treatment of essential hypertension with felodipine in combination with a diuretic.

Authors:  T Hedner; O Samuelsson; E Sjögren; D Elmfeldt
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Place of calcium antagonists in antihypertensive therapy: introduction and round-table discussion.

Authors:  F R Bühler; A Distler; J H Laragh; D Tourkantonis; G Valdes; M A Weber
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

5.  Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1985-04

6.  Felodipine kinetics in healthy men.

Authors:  B Edgar; C G Regårdh; G Johnsson; L Johansson; P Lundborg; I Löfberg; O Rönn
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

7.  Renal and cardiovascular effects of acute and chronic administration of felodipine to SHR.

Authors:  M Nordlander; G F Di Bona; B Ljung; T Yao; P Thorén
Journal:  Eur J Pharmacol       Date:  1985-07-11       Impact factor: 4.432

8.  Acute diuretic/natriuretic properties of felodipine in man.

Authors:  B Edgar; B Bengtsson; D Elmfeldt; P Lundborg; G Nyberg; S Raner; O Rönn
Journal:  Drugs       Date:  1985       Impact factor: 9.546

9.  Absorption, distribution and elimination of felodipine in man.

Authors:  B Edgar; K J Hoffmann; P Lundborg; C G Regårdh; O Rönn; L Weidolf
Journal:  Drugs       Date:  1985       Impact factor: 9.546

10.  Vascular selectivity of felodipine.

Authors:  B Ljung
Journal:  Drugs       Date:  1985       Impact factor: 9.546

View more
  10 in total

1.  Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function.

Authors:  P A Soons; T Ankermann; D D Breimer; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 3.  Approaches to meeting the criteria for fixed dose antihypertensive combinations. Focus on metoprolol.

Authors:  M J Kendall
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 4.  Felodipine clinical pharmacokinetics.

Authors:  P H Dunselman; B Edgar
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 5.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

6.  Felodipine in the treatment of patients with severe hypertension and impaired renal function.

Authors:  R Larsson; M K Lindsjö; B Danielsson; U Bengtsson; J H Hardlund; P A Sjöström; D Elmfeldt; L Moberg
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

7.  Comparative effects of felodipine, nitrendipine and nifedipine in healthy subjects: concentration-effect relationships of racemic drugs and enantiomers.

Authors:  P A Soons; A F Cohen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Pharmacokinetics of felodipine in patients with liver disease.

Authors:  C G Regårdh; B Edgar; R Olsson; M Kendall; P Collste; C Shansky
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 9.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

10.  A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling.

Authors:  Laura Maria Fuhr; Fatima Zahra Marok; Maximilian Mees; Felix Mahfoud; Dominik Selzer; Thorsten Lehr
Journal:  Pharmaceutics       Date:  2022-07-15       Impact factor: 6.525

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.